GlassScriptPhysician profile
Meghan Bishop
NPI 1629334941
$17,755.17
in general payments reported to CMS, 2019-2025
15 companies · $313 in 2025
The $313 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,341 · 2020: $2,487 · 2021: $3,776 · 2022: $1,459 · 2023: $62.73 · 2024: $3,315 · 2025: $313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $3,000 · Food and Beverage: $691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $3,000.00 |
| Food and Beverage | $691.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gotham Surgical Solutions & Devices, INC. | $6,923.58 | 2019-2022 | |
| Arthrex, INC. | $5,014.21 | 2019-2020 | |
| Averitas Pharma INC. | $3,044.67 | 2024 | |
| Stryker Corporation | $876.56 | 2019-2025 | Augment Injectable |
| Eclipse Technology Solutions INC. | $516.29 | 2022-2025 | |
| Smith+Nephew, INC. | $348.25 | 2019-2025 | Healicoil, Novostitch |
| Wright Medical Technology, INC. | $269.23 | 2019 | |
| Depuy Synthes Sales INC. | $266.73 | 2019-2023 | Monovisc |
| Acumed LLC | $149.47 | 2019 | |
| Vericel Corporation | $106.01 | 2021 | |
| Arthrosurface Incorporated | $101.65 | 2019 | |
| Ferring Pharmaceuticals INC. | $59.70 | 2019-2025 | Euflexxa |
| Bioventus LLC | $38.53 | 2022 | |
| Catalyst Orthoscience | $28.07 | 2022 | |
| Horizon Therapeutics Plc | $12.22 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Bishop listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.